CME Certificates will be issued digitally after Speaker Evaluations and Overall Surveys are completed. Surveys are accessible after logging in with the email address you submitted during registration. Surveys will be available online starting the day of the symposium. You must complete the process by February 22, 2021 in order to receive your certificate. Certificates will be available online until August 1 and are printable directly from the website.
The AAFP has reviewed the 21st Annual San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians and deemed it acceptable for up to 7.75 Online Only, Live AAFP Prescribed credits. Term of Approval is from 01/29/2021 to 01/30/2021. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Approval for AAFP CME credit does not imply authorization to use the AAFP logo on CME activity materials or to use AAFP's name in any association with the activity other than the credit statement.
The AAFP reserves the right to perform a post - activity audit and / or have a live monitor at any AAFP certified CME activity.
AMA / AAFP Equivalency: AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.
This year’s 21st Annual San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians will use a virtual platform for providing an up to data analysis of new and emerging trends in the management of patients with heart failure. There have been numerous advances in heart failure over the past year and we plan to highlight the most important ones and to put them into the context of on-going management strategies. The topics included in this year’s symposium include new approaches for modification of risk factors like hypertension, lipids and diabetes, a deep dive into the management of HFpEF and exciting new approaches for treating patients with amyloid heart disease, insights into newer drugs including the ARNIs, SGLT2 inhibitors, vericiguat, omecamtiv mecarbil and the potassium lowering agents as well as the expanding use of NOACs, role of biomarkers in heart failure management, an overview of devices to detect worsening of heart failure and the treatment of pulmonary arterial hypertension. There will also be updates on the most effective use of pacemakers, defibrillators and wearable devices, and percutaneous and durable mechanical support of the failing heart. We’ve had great success in weaving live panel and case discussions and Q/A panels into this year’s agenda so that registrants will have the opportunity to interact with the internationally renowned faculty that will presenting at the Symposium. In this way, the 21st Annual San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians will continue the tradition of the preceding ones in providing cutting edge information about heart failure by experts in the field in a format that enhances adaption into clinical practice. We’re looking forward to seeing you online on January 29-30, 2021.
This course is designed for cardiologists, internists, primary care physicians, nurses, PA’s, PharmD’s and all other allied healthcare professionals with an interest in heart failure.
At the conclusion of this activity, participants should be able to:
Over five million Americans (two percent of the U.S.) are living with heart failure (HF). An estimated 670,000 new cases of HF are diagnosed each year and this condition is a major cause of morbidity and mortality (80% of men and 70% of women less than 65 years of age who have HF will die within 8 years) and is the number one cause of hospitalizations of the elderly in the U.S. HF is common, but unrecognized and often misdiagnosed. Recent data have shown that drugs and devices that have proven beneficial and are recommended in recent practice guidelines, (HFSA 2010 update of practice guidelines Lindelfield J et al J Cardiac Failure 2010:16; 475) are underutilized (Fonarow GC et al. Circulation 2010;122:585).
Recent information also suggests a significant individual variability in conformity to quality-of-care indicators and clinical outcome of patients with HF and a substantial gap in overall performance. In addition, according to a study analyzing the quality of health care in the U.S. on average, patients with heart failure received the recommended quality of care only 64% of the time (heart failure performance measurement set by the ACC/AHA 2010).
Despite important advances in treatment, patients with HF continue to experience unacceptably high rates of morbidity and mortality. This along with the enormous cost of caring for a growing number of HF patients has resulted in increased scrutiny of existing and emerging therapies.